Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.
Yi-Long Wu 2, Martin Schuler 3, Martin Sebastian 4, Sanjay Popat 5, Nobuyuki Yamamoto 6, Caicun Zhou 7, Cheng-Ping Hu 8, Kenneth O'Byrne 9, Jifeng Feng 10, Shun Lu 11, Yunchao Huang 12, Sarayut L Geater 13, Kye Young Lee 14, Chun-Ming Tsai 15, Vera Gorbunova [ 16](#full-view-affiliation-16 "FSBI "N N Blokhin Russian Cancer Research Centre", Russian Academy of Medical Sciences, Moscow, Russia."), Vera Hirsh 17, Jaafar Bennouna 18, Sergey Orlov 19, Tony Mok 20, Michael Boyer 21, Wu-Chou Su 22, Ki Hyeong Lee 23, Terufumi Kato 24, Dan Massey 25, Mehdi Shahidi 25, Victoria Zazulina 25, Lecia V Sequist 26
Affiliations
- PMID: 25589191
- DOI: 10.1016/S1470-2045(14)71173-8
Free article
Clinical Trial
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al. Lancet Oncol. 2015 Feb.
Free article
Abstract
Background: We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials.
Methods: Previously untreated patients with EGFR mutation-positive stage IIIB or IV lung adenocarcinoma were enrolled in LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). These patients were randomly assigned in a 2:1 ratio to receive afatinib or chemotherapy (pemetrexed-cisplatin [LUX-Lung 3] or gemcitabine-cisplatin [LUX-Lung 6]), stratified by EGFR mutation (exon 19 deletion [del19], Leu858Arg, or other) and ethnic origin (LUX-Lung 3 only). We planned analyses of mature overall survival data in the intention-to-treat population after 209 (LUX-Lung 3) and 237 (LUX-Lung 6) deaths. These ongoing studies are registered with ClinicalTrials.gov, numbers NCT00949650 and NCT01121393.
Findings: Median follow-up in LUX-Lung 3 was 41 months (IQR 35-44); 213 (62%) of 345 patients had died. Median follow-up in LUX-Lung 6 was 33 months (IQR 31-37); 246 (68%) of 364 patients had died. In LUX-Lung 3, median overall survival was 28.2 months (95% CI 24.6-33.6) in the afatinib group and 28.2 months (20.7-33.2) in the pemetrexed-cisplatin group (HR 0.88, 95% CI 0.66-1.17, p=0.39). In LUX-Lung 6, median overall survival was 23.1 months (95% CI 20.4-27.3) in the afatinib group and 23.5 months (18.0-25.6) in the gemcitabine-cisplatin group (HR 0.93, 95% CI 0.72-1.22, p=0.61). However, in preplanned analyses, overall survival was significantly longer for patients with del19-positive tumours in the afatinib group than in the chemotherapy group in both trials: in LUX-Lung 3, median overall survival was 33.3 months (95% CI 26.8-41.5) in the afatinib group versus 21.1 months (16.3-30.7) in the chemotherapy group (HR 0.54, 95% CI 0.36-0.79, p=0.0015); in LUX-Lung 6, it was 31.4 months (95% CI 24.2-35.3) versus 18.4 months (14.6-25.6), respectively (HR 0.64, 95% CI 0.44-0.94, p=0.023). By contrast, there were no significant differences by treatment group for patients with EGFR Leu858Arg-positive tumours in either trial: in LUX-Lung 3, median overall survival was 27.6 months (19.8-41.7) in the afatinib group versus 40.3 months (24.3-not estimable) in the chemotherapy group (HR 1.30, 95% CI 0.80-2.11, p=0.29); in LUX-Lung 6, it was 19.6 months (95% CI 17.0-22.1) versus 24.3 months (19.0-27.0), respectively (HR 1.22, 95% CI 0.81-1.83, p=0.34). In both trials, the most common afatinib-related grade 3-4 adverse events were rash or acne (37 [16%] of 229 patients in LUX-Lung 3 and 35 [15%] of 239 patients in LUX-Lung 6), diarrhoea (33 [14%] and 13 [5%]), paronychia (26 [11%] in LUX-Lung 3 only), and stomatitis or mucositis (13 [5%] in LUX-Lung 6 only). In LUX-Lung 3, neutropenia (20 [18%] of 111 patients), fatigue (14 [13%]) and leucopenia (nine [8%]) were the most common chemotherapy-related grade 3-4 adverse events, while in LUX-Lung 6, the most common chemotherapy-related grade 3-4 adverse events were neutropenia (30 [27%] of 113 patients), vomiting (22 [19%]), and leucopenia (17 [15%]).
Interpretation: Although afatinib did not improve overall survival in the whole population of either trial, overall survival was improved with the drug for patients with del19 EGFR mutations. The absence of an effect in patients with Leu858Arg EGFR mutations suggests that EGFR del19-positive disease might be distinct from Leu858Arg-positive disease and that these subgroups should be analysed separately in future trials.
Funding: Boehringer Ingelheim.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
- LUX-Lung: determining the best EGFR inhibitor in NSCLC?
Rossi A, Di Maio M. Rossi A, et al. Lancet Oncol. 2015 Feb;16(2):118-9. doi: 10.1016/S1470-2045(14)71196-9. Epub 2015 Jan 12. Lancet Oncol. 2015. PMID: 25589190 No abstract available. - Targeted therapies: LUX-Lung trials-not all mutations are created equal.
Hutchinson L. Hutchinson L. Nat Rev Clin Oncol. 2015 Mar;12(3):127. doi: 10.1038/nrclinonc.2015.9. Epub 2015 Jan 27. Nat Rev Clin Oncol. 2015. PMID: 25622977 No abstract available.
Similar articles
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Wu YL, et al. Lancet Oncol. 2014 Feb;15(2):213-22. doi: 10.1016/S1470-2045(13)70604-1. Epub 2014 Jan 15. Lancet Oncol. 2014. PMID: 24439929 Clinical Trial. - Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N. Kato T, et al. Cancer Sci. 2015 Sep;106(9):1202-11. doi: 10.1111/cas.12723. Epub 2015 Jul 25. Cancer Sci. 2015. PMID: 26094656 Free PMC article. Clinical Trial. - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Sequist LV, et al. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816960 Clinical Trial. - Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Lee CK, et al. J Natl Cancer Inst. 2013 May 1;105(9):595-605. doi: 10.1093/jnci/djt072. Epub 2013 Apr 17. J Natl Cancer Inst. 2013. PMID: 23594426 Review. - Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM. Keating GM. Drugs. 2014 Feb;74(2):207-21. doi: 10.1007/s40265-013-0170-8. Drugs. 2014. PMID: 24435321 Review.
Cited by
- Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung Adenocarcinoma.
Lin JX, Yin K, Yan LX, Zheng MM, Li YS, Zhang SL, Zeng KH, Yan HH, Tu HY, Chen ZH, Zhang XC, Zhou Q, Yang JJ, Jiang BY, Zhang QL, Wu YL. Lin JX, et al. JTO Clin Res Rep. 2024 Jul 6;5(9):100704. doi: 10.1016/j.jtocrr.2024.100704. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39282661 Free PMC article. - Simultaneous lung and renal squamous cell carcinoma: A diagnostic and treatment challenge.
Zhang F, Sun WC, Sun JN, Tang GL, Chen X, Zhao HW. Zhang F, et al. Urol Case Rep. 2024 Aug 18;56:102825. doi: 10.1016/j.eucr.2024.102825. eCollection 2024 Sep. Urol Case Rep. 2024. PMID: 39247688 Free PMC article. - Adverse Events in Osimertinib Treatment for EGFR-Mutated Non-Small-Cell Lung Cancer: Unveiling Rare Life-Threatening Myelosuppression.
Shalata W, Abu Jama A, Dudnik Y, Abu Saleh O, Shalata S, Tourkey L, Sheva K, Meirovitz A, Yakobson A. Shalata W, et al. Medicina (Kaunas). 2024 Aug 6;60(8):1270. doi: 10.3390/medicina60081270. Medicina (Kaunas). 2024. PMID: 39202551 Free PMC article. - Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
Tompkins W, Grady CB, Hwang WT, Chandrasekhara K, McCoach C, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Montenegro GLB, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Marmarelis ME, Sun L. Tompkins W, et al. JTO Clin Res Rep. 2024 Mar 26;5(8):100669. doi: 10.1016/j.jtocrr.2024.100669. eCollection 2024 Aug. JTO Clin Res Rep. 2024. PMID: 39157674 Free PMC article. - From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond.
Zhou Y, Yao Z, Lin Y, Zhang H. Zhou Y, et al. Pharmaceutics. 2024 Jul 1;16(7):888. doi: 10.3390/pharmaceutics16070888. Pharmaceutics. 2024. PMID: 39065585 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous